FDA to decide on Roche’s lymphoma drug Lunsumio before year-end

FDA to decide on Roche’s lymphoma drug Lunsumio before year-end

Source: 
Pharmaforum
snippet: 

The FDA has granted a priority review to Roche’s T-cell engager Lunsumio as a treatment for follicular lymphoma (FL), setting up a decision on the drug by 29 December.